Compass Therapeutics Inc. CMPX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-11-13 |
| Shares Out. | 180,090,000 |
| Website | compasstherapeutics.com/ ↗ |
| Phone | 13026587581 |
| Employees | 39 |
| Net Income | -$18.3M |
| Free Cash Flow | -$53.3M |
| Total Assets | $205.2M |
| Total Liabilities | $18.7M |
| Equity | $186.5M |
About Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Compass Therapeutics Inc. is a publicly traded company under the ticker symbol CMPX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-07-01)